Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.60 |
| ▸ | CNR1 | P21554 | 6/20 | 0.59 |
| ▸ | TGM2 | P21980 | 10/20 | 0.56 |
| ▸ | F13A1 | P00488 | 7/20 | 0.56 |
| ▸ | TGM1 | P22735 | 4/20 | 0.56 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253160 | 0.86 | POLB (0.70) | STSCNR1TGM2F13A1TGM1 | |
| SCHEMBL3210642 | 0.84 | TGM2 (0.59) | STSTGM2F13A1TGM1TGM3 | |
| SCHEMBL5202414 | 0.83 | STS (0.57) | STSTGM2F13A1TGM1TGM3 | |
| SCHEMBL29060789 | 0.82 | MAPT (0.73) | STSCNR1TGM2F13A1TGM1 | |
| SCHEMBL17062363 | 0.81 | STS (0.47) | STSCNR1TGM2F13A1TGM1 | |
| SCHEMBL5738625 | 0.81 | TGM2 (0.56) | STSTGM2F13A1TGM1TGM3 | |
| SCHEMBL2252120 | 0.81 | TGM2 (0.63) | TGM2F13A1TGM1 | |
| SCHEMBL392870 | 0.80 | KMT2A (0.64) | STSTGM2F13A1TGM1TGM3 | |
| SCHEMBL16771053 | 0.80 | STS (0.69) | STS | |
| SCHEMBL2822128 | 0.80 | CNR1 (0.50) | STSCNR1TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-105793238-B | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2019-12-24 | — | — | CN | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3074377-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | STS 37/4885CNR1 481/4885TGM2 3970/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | STS 125/4885CNR1 499/4885TGM2 4271/4885 |
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | STS 3943/4885CNR1 1/4885TGM2 2919/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | STS 65/4885CNR1 126/4885TGM2 3672/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | STS 37/4885CNR1 481/4885TGM2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.